ArticlePloS one2013
High resolution crystal structure of human β-glucuronidase reveals structural basis of lysosome targeting.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 56 citations in OpenAlex.
- Non-invasive profiling of exosomal miRNA and protein biomarkers from vaginal discharge for the early detection of preterm labor.Journal of nanobiotechnology · 2026Article
- In Silico Structural Analysis of Human β-Glucuronidase for Antibody-Drug Conjugates Optimization.Proteins · 2026Article
- Coevolution of Rumen Epithelial circRNAs with Their Microbiota and Metabolites in Response to Cold-Season Nutritional Stress in Tibetan Sheep.International journal of molecular sciences · 2022Article
- Description of the molecular and clinical characteristics of the mucopolysaccharidosis type VII Iberian cohort.Orphanet journal of rare diseases · 2021Article
- Exploiting the Potential ofBiomedicines · 2021Review
- First Report of a Patient with MPS Type VII, Due to Novel Mutations inInternational journal of molecular sciences · 2019Article
- Synthesis, Molecular Docking and β-Glucuronidase Inhibitory Potential of Indole Base Oxadiazole Derivatives.Molecules (Basel, Switzerland) · 2019Article
- Oral manifestations in patients and dogs with mucopolysaccharidosis Type VII.American journal of medical genetics. Part A · 2019Article
- X-Ray Crystallography in Structure-Function Characterization of Therapeutic Enzymes.Advances in experimental medicine and biology · 2019Review
- Neuromuscular degeneration and locomotor deficit in aDisease models & mechanisms · 2018Article
- β-Glucuronidases of opportunistic bacteria are the major contributors to xenobiotic-induced toxicity in the gut.Scientific reports · 2018Article
- An Atlas of β-Glucuronidases in the Human Intestinal Microbiome.Structure (London, England : 1993) · 2017Article
- Epidemiology of mucopolysaccharidoses.Molecular genetics and metabolism · 2017Article
- Elevation of glycosaminoglycans in the amniotic fluid of a fetus with mucopolysaccharidosis VII.Prenatal diagnosis · 2017Article
- Annexin-directed β-glucuronidase for the targeted treatment of solid tumors.Protein engineering, design & selection : PEDS · 2017Article
- Sequence Analysis of Hypothetical Proteins fromGenomics & informatics · 2016Article
- Purification and characterization of RGA2, a Rho2 GTPase-activating protein from Tinospora cordifolia.3 Biotech · 2016Article
- Chitinase from Thermomyces lanuginosus SSBP and its biotechnological applications.Extremophiles : life under extreme conditions · 2015Review
- Structure-based function analysis of putative conserved proteins with isomerase activity from Haemophilus influenzae.3 Biotech · 2015Article
- Structure and Inhibition of Microbiome β-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.Chemistry & biology · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human β-glucuronidase (GUS) cleaves β-D-glucuronic acid residues from the non-reducing termini of glycosaminoglycan and its deficiency leads to mucopolysaccharidosis type VII (MPSVII). Here we report a high resolution crystal structure of human GUS at 1.7 Å resolution and present an extensive analysis of the structural features, unifying recent findings in the field of lysosome targeting and glycosyl hydrolases. The structure revealed several new details including a new glycan chain at Asn272, in addition to that previously observed at Asn173, and coordination of the glycan chain at Asn173 with Lys197 of the lysosomal targeting motif which is essential for phosphotransferase recognition. Analysis of the high resolution structure not only provided new insights into the structural basis for lysosomal targeting but showed significant differences between human GUS, which is medically important in its own right, and E. coli GUS, which can be selectively inhibited in the human gut to prevent prodrug activation and is also widely used as a reporter gene by plant biologists. Despite these differences, both human and E. coli GUS share a high structure homology in all three domains with most of the glycosyl hydrolases, suggesting that they all evolved from a common ancestral gene.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.